| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | -10.99 M USD | -6.93 M USD | -8.51 M USD | -6.43 M USD | -3.15 M USD |
| Depreciation & Amortization | 132540 USD | 773904 USD | 882177 USD | 654572 USD | 28699 USD |
| Stock-Based Compensation | — | 520830 USD | 963023 USD | 1.01 M USD | 1.20 M USD |
| Capital Expenditures | — | 138804 USD | 698277 USD | 542662 USD | 2.22 M USD |
| Cash Flow from Investing | -187.52 M USD | -1.16 M USD | -698277 USD | -3.12 M USD | -2.34 M USD |
| Cash Flow from Financing | 215.51 M USD | 5.91 M USD | 8.03 M USD | 12.24 M USD | 5.18 M USD |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — |
| Free Cash Flow | — | -7.07 M USD | -9.21 M USD | -6.98 M USD | -5.37 M USD |
SkyAI, Inc. Common Stock represents an equity interest in SkyAI, Inc., a company operating in the healthcare technology and medical equipment space. The company focuses on applying advanced artificial intelligence and data-driven tools to clinical and operational workflows, aiming to support healthcare providers in diagnosis, treatment planning, and resource management. SkyAI, Inc. develops software-enabled solutions that can integrate with existing medical systems, helping hospitals, clinics, and other care settings enhance decision support and efficiency. Its offerings are positioned within the broader medical equipment and health technology ecosystem, interacting with imaging platforms, electronic health records, and related digital infrastructure. SkyAI, Inc. primarily serves institutional healthcare customers and partners in the life sciences and health services sectors. Headquartered in the United States, the company participates in a competitive, innovation-intensive segment of the healthcare market, where artificial intelligence and machine learning play an increasingly central role in clinical and operational decision-making.